[go: up one dir, main page]

PE20221727A1 - Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos - Google Patents

Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos

Info

Publication number
PE20221727A1
PE20221727A1 PE2022002091A PE2022002091A PE20221727A1 PE 20221727 A1 PE20221727 A1 PE 20221727A1 PE 2022002091 A PE2022002091 A PE 2022002091A PE 2022002091 A PE2022002091 A PE 2022002091A PE 20221727 A1 PE20221727 A1 PE 20221727A1
Authority
PE
Peru
Prior art keywords
receptor agonist
agonist peptide
gip receptor
peptide compounds
dosage
Prior art date
Application number
PE2022002091A
Other languages
English (en)
Inventor
Antoine Charles Olivier Henninot
Derek Cecil Cole
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20221727A1 publication Critical patent/PE20221727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgacion proporciona compuestos peptidicos agonistas del receptor de GIP adecuados para dosificacion una vez a la semana (QW), en los que dichos compuestos peptidicos tienen una accion activadora sobre los receptores de GIP, y el uso del peptido agonista del receptor de GIP como medicamento para el tratamiento y/o la prevencion de la emesis o un sintoma o una afeccion asociados con la emesis. Especificamente, se proporciona un peptido agonista del receptor de GIP que contiene una secuencia representada por cualquiera de las formulas (I)-(V) o una sal de este y un medicamento que lo comprende.
PE2022002091A 2020-03-25 2021-03-25 Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos PE20221727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994721P 2020-03-25 2020-03-25
PCT/JP2021/014422 WO2021193983A2 (en) 2020-03-25 2021-03-25 Qw dosing of gip receptor agonist peptide compounds and uses thereof

Publications (1)

Publication Number Publication Date
PE20221727A1 true PE20221727A1 (es) 2022-11-04

Family

ID=75674909

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002091A PE20221727A1 (es) 2020-03-25 2021-03-25 Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos

Country Status (18)

Country Link
US (1) US20230143604A1 (es)
EP (1) EP4126920A2 (es)
JP (1) JP2023524603A (es)
KR (1) KR20220157409A (es)
CN (1) CN115916812A (es)
AR (1) AR121649A1 (es)
AU (1) AU2021243671A1 (es)
BR (1) BR112022019110A2 (es)
CA (1) CA3172241A1 (es)
CL (1) CL2022002597A1 (es)
CO (1) CO2022014960A2 (es)
EC (1) ECSP22074715A (es)
IL (1) IL296219A (es)
MX (1) MX2022011729A (es)
PE (1) PE20221727A1 (es)
PH (1) PH12022552561A1 (es)
TW (1) TW202202517A (es)
WO (1) WO2021193983A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3226003A1 (en) * 2021-07-16 2023-01-19 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
WO2006121904A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP2431367A3 (en) 2006-06-27 2012-07-04 Takeda Pharmaceutical Company Limited Fused cyclic compounds as GPR40 receptor modulators
AU2007284365A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
BRPI0807014A2 (pt) 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN104231070B (zh) * 2008-08-07 2017-09-01 益普生制药股份有限公司 N‑端修饰的葡萄糖依赖性促胰岛素多肽（gip）类似物
JOP20180028A1 (ar) * 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
PH12022552562A1 (en) * 2020-03-25 2022-12-19 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof

Also Published As

Publication number Publication date
CN115916812A (zh) 2023-04-04
ECSP22074715A (es) 2022-10-31
WO2021193983A8 (en) 2023-05-25
CL2022002597A1 (es) 2023-06-02
AR121649A1 (es) 2022-06-22
CO2022014960A2 (es) 2022-11-08
WO2021193983A2 (en) 2021-09-30
MX2022011729A (es) 2022-10-13
PH12022552561A1 (en) 2024-04-22
CA3172241A1 (en) 2021-09-30
KR20220157409A (ko) 2022-11-29
EP4126920A2 (en) 2023-02-08
TW202202517A (zh) 2022-01-16
WO2021193983A3 (en) 2021-11-04
US20230143604A1 (en) 2023-05-11
AU2021243671A1 (en) 2022-10-13
IL296219A (en) 2022-11-01
JP2023524603A (ja) 2023-06-12
BR112022019110A2 (pt) 2023-01-17

Similar Documents

Publication Publication Date Title
CL2022002597A1 (es) Dosificación qw de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2022014959A2 (es) Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
CO2019012271A2 (es) Péptido activador de receptor de gip
MX2023011675A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
ECSP15044389A (es) Compuesto peptídico
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
CL2017001024A1 (es) Formulación de buprenorfina inyectable
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
MX2021015654A (es) Antagonista del receptor 2 de prostaglandina e2 (ep2).
CO2018011353A2 (es) Dispositivo de inyección mecánico para descargar múltiples formulaciones líquidas, incluso vacunas
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
AR101806A1 (es) Derivados de 1-acetil-4-amino-1,2,3,4-tetrahidroquinolina, composición farmacéutica que los comprende y su uso en el tratamiento de afecciones mediadas por un inhibidor de bromodominio
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
MX390507B (es) Compuestos de amida y su uso.
CO2020002967A2 (es) Desinfectante novedoso para criaderos
AR102248A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y tratamiento de la diabetes
AR121581A1 (es) Formulaciones líquidas de análogos de glucagón